Acunivive 90 Injection System and Calquence

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using acalabrutinib together with ketorolac may increase the risk of bleeding. In clinical studies, treatment with acalabrutinib alone has been associated with severe and sometimes fatal hemorrhage. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Serious and fatal hemorrhagic events have been reported during acalabrutinib therapy. In the combined safety database of 612 patients with hematologic malignancies treated with acalabrutinib monotherapy, grade 3 or higher bleeding events including gastrointestinal, intracranial, and epistaxis occurred in 2% of patients. Overall, bleeding events of any grade occurred in approximately 50% of patients. The mechanism for the bleeding events is not well understood, although treatment with acalabrutinib commonly causes thrombocytopenia. Treatment-emergent grade 3 or 4 thrombocytopenia was reported in 8% of patients in the combined safety database, while thrombocytopenia of all grades was reported in greater than 40% of patients.

MANAGEMENT: Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin or other vitamin K antagonists. Patients should be advised to promptly report any signs of bleeding to their physician.

Acunivive 90 Injection System

Generic Name: ketorolac

Brand name: Sprix, Toradol

Synonyms: Ketorolac (nasal), Ketorolac (Nasal)

What is Acunivive 90 Injection System?

Calquence

Generic Name: acalabrutinib

Brand name: Calquence

Synonyms: n.a.

What is Calquence?